Berlin Cures GmbH
Berlin Cures GmbH is a spin-off company founded in September 2014 in order to bring a successful research project to the market. A group of scientists from the Max Delbrück Center (MDC), the Charité Berlin and the German Heart Institute Berlin has been studying the significance of autoantibodies in heart disease and other autoimmune diseases for over 10 years. Gerd Wallukat from the MDC discovered these autoantibodies and described them for the first time in 1987. They have the special characteristic of stimulating cells via a highly specific signal pathway (so-called G-protein-coupled receptors) thereby sending pathological information and activating the cells in such a way that leads to long-term organ damage. The researchers have now found a drug (an aptamer) that can neutralize these autoantibodies in the patient’s blood. The scientists will continue their work at Berlin Cures, using their expertise to support the drug approval process and to identify further diseases that are induced or maintained by autoantibodies. The idea of binding autoantibodies with a highly specific aptamer is protected by two patents exclusively licensed to Berlin Cures for commercial exploitation.
Our drug candidate BC007
Our drug candidate BC007 is a 15mer aptamer, that binds to and neutralizes functional autoantibodies directed against the beta1-(GPCR)-receptor. Pre-clinical studies of BC007 to support the application for the phase 1 clinical study showed that BC007 was well tolerated with no adverse dose identified.
The first indication that Berlin Cures pursues is chronic congestive heart failure in patients that are positive for GPCR autoantibodies. Autoantibodies against GPCR-receptors are not only associated to chronic congestive heart failure but also to a number of other autoimmune diseases. Berlin Cures will expand the field of indications in the near future.